Comparison of cardiotoxicity between N-methyl-glucamine and miltefosine in the treatment of American cutaneous leishmaniasis

No evidence for cardiotoxicity of miltefosine – Reply

“…The authors are pleased to read Professor Dorlos’ comments on the article that we published in this journal. 1 As the professor rightly states cardiotoxicity of Meglumine Antimoniate (NMG) is well established, and there is no convincing pharmacokinetic evidence that miltefosine causes cardiotoxicity. We, however, cannot arrive at any specific conclusion on the pharmacokinetics of miltefosine based on our data as we have not investigated drug absorption, distribution, metabolism, or excretion in this study.…”

No evidence for cardiotoxicity of miltefosine

“…In a recent article, Barroso et al 1 reported on the comparison of cardiotoxicity between N-methyl glucamine antimoniate, better known as meglumine antimoniate, and miltefosine. As the authors indicate, antimonial compounds are notorious for their extensive toxicity, particularly cardiotoxicity, leading to pronounced prolongation of corrected QT interval (QTc) and risk of developing abnormal heart rhythms that can cause sudden death.…”